Sanofi to pay $462m to Regeneron in a revised immuno-oncology deal
Category: #health  By Pankaj Singh  Date: 2019-01-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sanofi to pay $462m to Regeneron in a revised immuno-oncology deal

The Paris-based multinational pharmaceutical firm, Sanofi S.A., would pay approximately $462 million to Regeneron, a New York-based biotech firm. Apparently, this move is the result of a revision of their deal in immuno-oncology, a booming sector in healthcare research that aims to assist the immune system of one’s body in fighting cancer.

Further from the reports, an agreement was signed between both the companies in 2015, and was due to end by mid-2020. Both the companies said in a statement that the new arrangement would provide an increased flexibility to Sanofi for advancing its pipeline of early-stage immuno-oncology, whereas the U.S. healthcare group Regeneron reserves all the rights to the company’s other immuno-oncology innovation as well as development programs.

Sanofi would allegedly pay US$ 462 million to Regeneron, representing the payments balance due under the companies’ original deal, that covers the share of the immuno-oncology discovery program costs incurred by Sanofi for the year 2018’s last quarter, as well as about US$ 120 million in various development costs.

Sources familiar with the matter said that Regeneron would be committing up to US$ 120 million, for its part, for funding new developments in the field. Regeneron and Sanofi also work together on developing the Dupixent product. This product is utilized in treating eczema and has had positive feedback from the regulators of the U.S.

The two companies already had success in joint development projects, like the recently launched Dupixent (dupilumab), an eczema drug, which is tipped for bringing in blockbuster-level sales, and the Praluent (alirocumab), the cholesterol drug, is in the market for several years.

Purportedly, an ongoing R&D agreement for development as well as marketing of a PD-1 antibody, Libtayo (cemiplimab), is unaffected and Regeneron reserves total rights to its other immune-oncology programs.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Incyte unveils positive results from Phase 2 ruxolitinib cream study
Incyte unveils positive results from Phase 2 ruxolitinib cream study
By Pankaj Singh

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continu...

Illumina inks a long-term NGS deal with Dutch company Qiagen
Illumina inks a long-term NGS deal with Dutch company Qiagen
By Pankaj Singh

The pharmaceutical industry is responsible for treating some of the most critical health issues. The sector produces, develops and markets drugs that could be beneficial to people on a larger scale. However, with ...

Graybug Vision commences Phase 2b Clinical study to target wet AMD
Graybug Vision commences Phase 2b Clinical study to target wet AMD
By Pankaj Singh

Macular degeneration is the leading cause of irreversible, serious vision loss that occurs when a section of the retina known as the macula is damaged. It is often observed that Age-Related Macular ...